市場調査レポート
商品コード
1411406

ゲノム編集の世界市場:技術流通に注力 (遺伝子編集技術の種類別、治療の種類別、遺伝子編集アプローチ別、遺伝子の送達方法別、主要地域別):産業動向と予測 (2023~2035年)

Genome Editing Market: Focus on Technology-Distribution by Type of Gene Editing Technique, Type of Therapy, Gene Editing Approach, Type of Gene Delivery Method, Key Geographical Regions & Distribution: Industry Trends & Global Forecasts, 2023-2035

出版日: | 発行: Roots Analysis | ページ情報: 英文 270 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
ゲノム編集の世界市場:技術流通に注力 (遺伝子編集技術の種類別、治療の種類別、遺伝子編集アプローチ別、遺伝子の送達方法別、主要地域別):産業動向と予測 (2023~2035年)
出版日: 2024年01月02日
発行: Roots Analysis
ページ情報: 英文 270 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界のゲノム編集の市場規模は、2023年に35億米ドルと評価され、予測期間中 (2023-2035年) に12.6%のCAGRで成長すると予測されます。

遺伝子編集 (遺伝子置換) は、生物のゲノム内の単一遺伝子 (または遺伝子配列) を改変 (挿入、削除、置換) するプロセスです。近年、ゲノム内の特定部位を編集する必要性が高まり、遺伝子編集企業による各種のゲノム編集ツール - ZFN (ジンクフィンガーヌクレアーゼ)、TALEN (組織脂肪様エフェクターヌクレアーゼ)、そして最近ではCRISPR (cRNAベース技術) など - の開発が急増しています。これらの遺伝子編集ツールは、鎌状赤血球症 (SCD)、パーキンソン病 (PDD)、難聴 (HELP)、末梢動脈疾患 (PAD)、脊髄性筋萎縮症 (SMA)、自己免疫疾患 (AML) など、遺伝子異常に起因する臨床症状を治療するための矯正戦略として広く用いられてきました。標的遺伝子の編集療法の創出に向けた取り組みが行われている中で、2023年現在、治験中の遺伝子治療候補は300種以上に達しています。特筆すべきは、予防治療も遺伝子編集応用市場で注目されている分野であることです。しかし、遺伝子編集された医薬品の開発には、遺伝子研究分野での多額の投資が伴うことに留意する必要があります。これらの医薬品を効率的、正確かつ安全に送達するために、製薬会社はゲノム編集企業が開発した新しいゲノム編集技術に依存しており、ひいては、必要な遺伝子操作を実現することで臨床結果を改善する上で医薬品開発者を支援することになります。有望な臨床試験結果と医薬品承認の加速化により、ゲノム編集市場は今後数年間で大きな成長が見込まれます。

当レポートでは、世界のゲノム編集市場について分析し、処置の概要や市場の基本構造・最新情勢、主な市場促進・抑制要因、全体的な市場規模の動向見通し、地域別 (全3地域)・セグメント別の詳細動向、昨今の主な事業提携・資本取引の動き (投資、M&Aなど)、特許の登録状況、現在の競合情勢、主要企業のプロファイルなどを調査しております。

主な市場参入企業

  • Arcturus Therapeutics
  • Avectas
  • Beam Therapeutics
  • Bio-Sourcing
  • Caribou Biosciences
  • Century Therapeutics
  • CRISPR Therapeutics
  • EdiGene
  • Editas Medicine
  • Flash Therapeutics
  • Fortgen
  • G+FLAS Life Sciences
  • Graphite Bio
  • Intellia Therapeutics
  • Ntrans Technologies
  • OXGENE
  • Prime Medicine
  • Revvity (formerly known as Horizon Discovery)
  • TargetGene Biotechnologies
  • Vor Biopharma
  • ZeClinics

目次

第1章 序論

第2章 調査手法

第3章 経済およびその他のプロジェクト特有の考慮事項

第4章 エグゼクティブサマリー

第5章 イントロダクション

  • ゲノム編集の概略
  • ゲノム編集技術の用途
  • その他の新興技術
  • 結論

第6章 技術情勢

  • ゲノム編集:技術の情勢
  • ゲノム編集:技術開発者の情勢

第7章 技術競争力の分析

  • 前提条件/主要パラメーター
  • 調査手法
  • 技術競争力の分析

第8章 企業プロファイル

  • Arcturus Therapeutics
  • Beam Therapeutics
  • Caribou Biosciences
  • Century Therapeutics
  • CRISPR Therapeutics
  • Editas Medicine
  • Graphite Bio
  • Intellia Therapeutics
  • Prime Medicine
  • Vor Biopharma
  • その他の主要企業

第9章 パートナーシップとコラボレーション

  • パートナーシップモデル
  • ゲノム編集技術:パートナーシップとコラボレーション

第10章 特許分析

  • 分析範囲・手法
  • ゲノム編集ドメイン:特許解析
  • ゲノム編集ドメイン:特許のベンチマーク分析
  • 特許の評価額の分析

第11章 資金調達と投資の分析

  • 資金の種類
  • ゲノム編集ドメイン:資金調達と投資分析

第12章 市場への影響分析:促進要因、抑制要因、機会、課題

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の課題
  • 結論

第13章 ゲノム編集技術の市場

  • 前提条件と調査手法
  • ゲノム編集技術市場:将来予測 (2023~2035年)
  • 主要な市場区分
  • ダイナミックダッシュボード

第14章 ゲノム編集技術市場:遺伝子編集技術の種類別

  • 主な前提条件と調査手法
  • CRISPR-Casシステム:予測値 (2023~2035年)
  • TALEN:予測値 (2023~2035年)
  • メガヌクレアーゼ:予測値 (2023~2035年)
  • ZFN:予測値 (2023~2035年)
  • その他の手法:予測値 (2023~2035年)
  • データの計測

第15章 ゲノム編集技術市場:治療の種類別

  • 主な前提条件と調査手法
  • 細胞療法:予測値 (2023~2035年)
  • 遺伝子治療:予測値 (2023~2035年)
  • その他の治療法:予測値 (2023~2035年)
  • データの計測

第16章 ゲノム編集技術市場:遺伝子編集アプローチ別

  • 主な前提条件と調査手法
  • 遺伝子ノックアウトアプローチ:予測値 (2023~2035年)
  • 遺伝子ノックインアプローチ:予測値 (2023~2035年)
  • データの計測

第17章 ゲノム編集技術市場:遺伝子の送達方法別

  • 主な前提条件と調査手法
  • Ex-Vivo (生体外) 送達方法:予測値 (2023~2035年)
  • In-Vivo (生体内) 送達方法:予測値 (2023~2035年)
  • データの計測

第18章 ゲノム編集技術市場:遺伝子導入モダリティ別

  • 主な前提条件と調査手法
  • ウイルスベクター:予測値 (2023~2035年)
  • 非ウイルスベクター:予測値 (2023~2035年)
  • データの計測

第19章 ゲノム編集技術市場:活用領域別

  • 主な前提条件と調査手法
  • 創薬・開発:予測値 (2023~2035年)
  • 診断:予測値 (2023~2035年)
  • データの計測

第20章 ゲノム編集技術市場:エンドユーザーの種類別

  • 主な前提条件と調査手法
  • 製薬企業・バイオテクノロジー企業:予測値 (2023~2035年)
  • 学術・研究機関:予測値 (2023~2035年)
  • データの計測

第21章 ゲノム編集技術市場:主要地域別

  • 主な前提条件と調査手法
  • 北米:予測値 (2023~2035年)
  • 欧州:予測値 (2023~2035年)
  • アジア太平洋:予測値 (2023~2035年)
  • データの計測

第22章 ゲノム編集技術市場:使用される決済手段の種類別

  • 主な前提条件と調査手法
  • マイルストーン払い:予測値 (2023~2035年)
  • 前払い:予測値 (2023~2035年)
  • データの計測

第23章 ゲノム編集技術市場:主な市場参入企業

  • 業界をリードする企業

第24章 結論

第25章 経営陣の洞察

第26章 付録1:表形式のデータ

第27章 付録2:企業および組織のリスト

目次
Product Code: RA100464

The genome editing marketis valued at USD 3.5 billion in 2023 growing at a CAGR of 12.6% during the forecast period 2023-2035.

Gene editing or gene replacement is the process of modifying (inserting, deleting or replacing) a single gene (or a sequence of genes) in the genome of a living organism. In recent years, the need to edit at a specific site within the genome has increased, there has been a surge in the development of different types of genome editing tools by gene-editing companies. These include ZFNs (zinc finger nucleases), TALENs (tissue-aliphatic-like-effector nucleases) and, most recently, CRISPR (cRNA-based technology). These gene-editing tools have been widely used as a corrective strategy to treat clinical conditions resulting from genetic abnormalities, including Sickle cell disease (SCD), Parkinson's disease (PDD), hearing loss (HELP), peripheral artery disease (PAD), spinal muscular atrophies (SMA), autoimmune diseases (AML) and other types of genetic disorders. In the midst of the current efforts to create targeted gene-editing therapies, there are more than 300 candidates for gene therapy in clinical trials as of 2023. It is worth mentioning, prophylaxis treatment is another segment that has attracted a lot of attention in the market of gene editing applications. However, it is important to note that the development of a gene edited drug product involves a significant investment in the development of drugs in the field of gene research. In order to deliver these drugs efficiently, precisely and safely, the pharma companies are relying on new genome editing technologies developed by the genome editing companies, which in turn will help the drug developers in improving the clinical outcome by achieving the required genetic manipulation. With encouraging clinical trial results and accelerated drug approval, the market for genome editing is expected to experience significant growth over the next few years.

Key Market Segments

Type of Gene Editing Technique

  • CRISPR-Cas System
  • TALENs
  • Meganucleases
  • ZFNs
  • Other Techniques

Type of Therapy

  • Cell Therapies
  • Gene Therapies
  • Other Therapies
  • Gene Editing Approach
  • Gene Knock-Out Approaches
  • Gene Knock- In Approaches
  • Gene Delivery Method
  • Ex-Vivo Delivery Methods
  • In-Vivo Delivery Methods
  • Gene Delivery Modality
  • Viral Vectors
  • Non-Viral Vectors
  • Application Area
  • Drug Discovery and Development
  • Diagnostics

Type of End User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific
  • Payment Method Employed
  • Upfront Payments
  • Milestone Payments

Research Coverage:

The report studies the genome editing market based on type of gene editing technique, type of therapy, gene editing approach, gene delivery method, gene delivery modality, application area, type of end user, key geographical regions and payment method employed.

The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.

The report forecasts the revenue of market segments with respect to three major regions

The report includes a brief introduction to genome editing, including the evolution of the domain over the years, a list of the different genome editing technologies, and an overview of how genome editing is being used in different industries such as biotechnology, pharma and agriculture. It also highlights the various cutting-edge genome editing technologies.

Comprehensive analysis of the current technology landscape for genome editing domain considering parameters such as type of gene editing technique (CRISPR-Cas system, meganucleases, TALENs, ZFNs and other techniques), gene editing approach, type of gene delivery method, type of gene delivery modality, highest phase of drug development supported, therapeutic area and application. In addition, the chapter features information on various technology developers, along with analysis based on multiple parameters, establishment year, company size, headquarters and operational model

Create detailed profiles of leading genome editing companies, including establishment year, employees, HQ location, key executives, technology portfolios, recent developments, and future outlook.

Detailed company competitiveness evaluation of medical aesthetics company, considering developer strength and technology strength in terms of type of gene editing technique, gene editing approach, in-silico (CADD) analysis, type of gene delivery method, type of gene delivery modality, highest phase of development supported and application area.

Examine partnerships (licensing agreements, research and development agreements, technology integration agreements, etc.) in the genome editing market from 2018-2023. Analyze recent investments (grants, funding rounds) and initiatives by market stakeholders.

Review patents related to genome editing from 2018-2023, highlighting types, publication years, locations, CPC symbols, focus areas, applicant types, and leading players.

The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the genome editing market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies

  • Arcturus Therapeutics
  • Avectas
  • Beam Therapeutics
  • Bio-Sourcing
  • Caribou Biosciences
  • Century Therapeutics
  • CRISPR Therapeutics
  • EdiGene
  • Editas Medicine
  • Flash Therapeutics
  • Fortgen
  • G+FLAS Life Sciences
  • Graphite Bio
  • Intellia Therapeutics
  • Ntrans Technologies

    OXGENE

  • Prime Medicine
  • Revvity (formerly known as Horizon Discovery)
  • TargetGene Biotechnologies
  • Vor Biopharma
  • ZeClinics

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Key Market Insights
  • 1.3. Scope of the Report
  • 1.4. Research Methodology
  • 1.5. Frequently Asked Questions
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact / Related Factors
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past

Recessions and Lessons Learnt

      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Introduction to Genome Editing
    • 5.2.1. Evolution of Genome Editing
    • 5.2.2. Genome Editing Technologies
      • 5.2.2.1. CRISPR - Cas System
      • 5.2.2.2. Transcription Activator-Like Effector Nucleases (TALENs)
      • 5.2.2.3. Zinc Finger Nucleases (ZFNs)
      • 5.2.2.4. Meganucleases / Homing Endonucleases
  • 5.3. Applications of Genome Editing Technologies
  • 5.4. Other Emerging Technologies
  • 5.5. Concluding Remarks

6. TECHNOLOGY LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Genome Editing: Technology Landscape
    • 6.2.1. Analysis by Type of Gene Editing Technique
    • 6.2.2. Analysis by Gene Editing Approach
    • 6.2.3. Analysis by Type of Gene Delivery Method
    • 6.2.4. Analysis by Type of Gene Delivery Modality
    • 6.2.5. Analysis by Highest Phase of Drug Development Supported
    • 6.2.6. Analysis by Therapeutic Area
    • 6.2.7. Analysis by Application Area
  • 6.3. Genome Editing: Technology Developer Landscape
    • 6.3.1. Analysis by Year of Establishment
    • 6.3.2. Analysis by Company Size
    • 6.3.3. Analysis by Location of Headquarters
    • 6.3.4. Analysis by Operational Model
    • 6.3.5. Most Active Players: Distribution by Number of Technologies

7. TECHNOLOGY COMPETITIVENESS ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Assumptions / Key Parameters
  • 7.3. Methodology
  • 7.4. Technology Competitiveness Analysis
    • 7.4.1. Genome Editing Technologies Offered by Players based in North America
    • 7.4.2. Genome Editing Technologies Offered by Players based in Europe
    • 7.4.3. Genome Editing Technologies Offered by Players based in Asia-Pacific, Middle East and North Africa, and Latin America

8. COMPANY PROFILES

  • 8.1. Chapter Overview
  • 8.2. Arcturus Therapeutics
    • 8.2.1. Company Overview
    • 8.2.2. Financial Information
    • 8.2.3. Technology Portfolio
    • 8.2.4. Recent Developments and Future Outlook
  • 8.3. Beam Therapeutics
    • 8.3.1. Company Overview
    • 8.3.2. Financial Information
    • 8.3.3. Technology Portfolio
    • 8.3.4. Recent Developments and Future Outlook
  • 8.4. Caribou Biosciences
    • 8.4.1. Company Overview
    • 8.4.2. Financial Information
    • 8.4.3. Technology Portfolio
    • 8.4.4. Recent Developments and Future Outlook
  • 8.5. Century Therapeutics
    • 8.5.1. Company Overview
    • 8.5.2. Financial Information
    • 8.5.3. Technology Portfolio
    • 8.5.4. Recent Developments and Future Outlook
  • 8.6. CRISPR Therapeutics
    • 8.6.1. Company Overview
    • 8.6.2. Financial Information
    • 8.6.3. Technology Portfolio
    • 8.6.4. Recent Developments and Future Outlook
  • 8.7. Editas Medicine
    • 8.7.1. Company Overview
    • 8.7.2. Financial Information
    • 8.7.3. Technology Portfolio
    • 8.7.4. Recent Developments and Future Outlook
  • 8.8. Graphite Bio
    • 8.8.1. Company Overview
    • 8.8.2. Technology Portfolio
    • 8.8.3. Recent Developments and Future Outlook
  • 8.9. Intellia Therapeutics
    • 8.9.1. Company Overview
    • 8.9.2. Financial Information
    • 8.9.3. Technology Portfolio
    • 8.9.4. Recent Developments and Future Outlook
  • 8.10. Prime Medicine
    • 8.10.1. Company Overview
    • 8.10.2. Technology Portfolio
    • 8.10.3. Recent Developments and Future Outlook
  • 8.11. Vor Biopharma
    • 8.11.1. Company Overview
    • 8.11.2. Technology Portfolio
    • 8.11.3. Recent Developments and Future Outlook
  • 8.12. Other Leading Players
    • 8.12.1. Avectas
    • 8.12.2. Bio-Sourcing
    • 8.12.3. Edigene
    • 8.12.4. Flash Therapeutics
    • 8.12.5. Fortgen
    • 8.12.6. G+FLAS Life Sciences
    • 8.12.7. Ntrans Technologies
    • 8.12.8. OXGENE
    • 8.12.9. Revvity (formerly known as Horizon Discovery)
    • 8.12.10. TargetGene Biotechnologies
    • 8.12.11. ZeClinics

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Genome Editing Technologies: Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Year and Type of Partnership
    • 9.3.4. Analysis by Type of Partner
    • 9.3.5. Analysis by Location of Headquarters of Partner
    • 9.3.6. Most Active Players: Analysis by Number of Partnerships
    • 9.3.7. Analysis by Geography
      • 9.3.7.1. Local and International Agreements
      • 9.3.7.2. Intercontinental and Intracontinental Agreements

10. PATENT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Genome Editing Domain: Patent Analysis
    • 10.3.1. Analysis by Publication Year
    • 10.3.2. Analysis by Type of Patent and Publication Year
    • 10.3.3. Analysis by Geography
    • 10.3.4. Analysis by CPC Symbols
    • 10.3.5. Leading Industry Players: Analysis by Number of Patents
  • 10.4. Genome Editing Domain: Patent Benchmarking Analysis
    • 10.4.1. Analysis by Patent Characteristics
    • 10.4.2. Analysis by Leading Industry Players
  • 10.5. Patent Valuation Analysis

11. FUNDING AND INVESTMENT ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Types of Funding
  • 11.3. Genome Editing Domain: Funding and Investment Analysis
    • 11.3.1. Analysis by Year of Investment
      • 11.3.1.1. Cumulative Year-wise Trend of Funding Instances
      • 11.3.1.2. Cumulative Year-wise Trend of Amount Invested
    • 11.3.2. Analysis by Type of Funding
      • 11.3.2.1. Analysis of Funding Instances
      • 11.3.2.2. Analysis of Amount Invested
    • 11.3.3. Analysis by Year and Type of Funding
    • 11.3.4. Analysis by Geography
    • 11.3.5. Most Active Players: Analysis by Amount Invested and Number of Funding Instances
    • 11.3.6. Leading Investors: Analysis by Number of Funding Instances

12. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 12.1. Chapter Overview
  • 12.2. Market Drivers
  • 12.3. Market Restraints
  • 12.4. Market Opportunities
  • 12.5. Market Challenges
  • 12.6. Conclusion

13. GENOME EDITING TECHNOLOGIES MARKET

  • 13.1. Chapter Overview
  • 13.2. Assumptions and Methodology
  • 13.3. Genome Editing Technologies Market, Forecasted Estimates (2023-2035)
    • 13.3.1. Scenario Analysis
  • 13.4. Key Market Segmentations
  • 13.5. Dynamic Dashboard

14. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF GENE EDITING TECHNIQUE

  • 14.1. Chapter Overview
  • 14.2. Key Assumptions and Methodology
  • 14.3. CRISPR-Cas System: Forecasted Estimates (2023-2035)
  • 14.4. TALENs: Forecasted Estimates (2023-2035)
  • 14.5. Meganucleases: Forecasted Estimates (2023-2035)
  • 14.6. ZFNs: Forecasted Estimates (2023-2035)
  • 14.7. Other Techniques: Forecasted Estimates (2023-2035)
  • 14.8. Data Triangulation
    • 14.8.1. Insights from Primary Research
    • 14.8.2. Insights from Secondary Research
    • 14.8.3. Insights from In-house Repository

15. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF THERAPY

  • 15.1. Chapter Overview
  • 15.2. Key Assumptions and Methodology
  • 15.3. Cell Therapies: Forecasted Estimates (2023-2035)
  • 15.4. Gene Therapies: Forecasted Estimates (2023-2035)
  • 15.5. Other Therapies: Forecasted Estimates (2023-2035)
  • 15.6. Data Triangulation
    • 15.6.1. Insights from Primary Research
    • 15.6.2. Insights from Secondary Research
    • 15.6.3. Insights from In-house Repository

16. GENOME EDITING TECHNOLOGIES MARKET, BY GENE EDITING APPROACH

  • 16.1. Chapter Overview
  • 16.2. Key Assumptions and Methodology
  • 16.3. Gene Knock-Out Approaches: Forecasted Estimates (2023-2035)
  • 16.4. Gene Knock-In Approaches: Forecasted Estimates (2023-2035)
  • 16.5. Data Triangulation
    • 16.5.1. Insights from Primary Research
    • 16.5.2. Insights from Secondary Research
    • 16.5.3. Insights from In-house Repository

17. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY METHOD

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Ex-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
  • 17.4. In-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
  • 17.5. Data Triangulation
    • 17.5.1. Insights from Primary Research
    • 17.5.2. Insights from Secondary Research
    • 17.5.3. Insights from In-house Repository

18. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY MODALITY

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Viral Vectors: Forecasted Estimates (2023-2035)
  • 18.4. Non-Viral Vectors: Forecasted Estimates (2023-2035)
  • 18.5. Data Triangulation
    • 18.5.1. Insights from Primary Research
    • 18.5.2. Insights from Secondary Research
    • 18.5.3. Insights from In-house Repository

19. GENOME EDITING TECHNOLOGIES MARKET, BY APPLICATION AREA

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Drug Discovery and Development: Forecasted Estimates (2023-2035)
  • 19.4. Diagnostics: Forecasted Estimates (2023-2035)
  • 19.5. Data Triangulation
    • 19.5.1. Insights from Primary Research
    • 19.5.2. Insights from Secondary Research
    • 19.5.3. Insights from In-house Repository

20. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF END USER

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Pharmaceutical and Biotechnology Companies: Forecasted Estimates (2023-2035)
  • 20.4. Academic and Research Institutes: Forecasted Estimates (2023-2035)
  • 20.5. Data Triangulation
    • 20.5.1. Insights from Primary Research
    • 20.5.2. Insights from Secondary Research
    • 20.5.3. Insights from In-house Repository

21. GENOME EDITING TECHNOLOGIES MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. North America: Forecasted Estimates (2023-2035)
  • 21.4. Europe: Forecasted Estimates (2023-2035)
  • 21.5. Asia-Pacific: Forecasted Estimates (2023-2035)
  • 21.6. Data Triangulation
    • 21.6.1. Insights from Primary Research
    • 21.6.2. Insights from Secondary Research
    • 21.6.3. Insights from In-house Repository

22. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF PAYMENT METHOD EMPLOYED

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. Milestone Payments: Forecasted Estimates (2023-2035)
  • 22.4. Upfront Payments: Forecasted Estimates (2023-2035)
  • 22.5. Data Triangulation
    • 22.5.1. Insights from Primary Research
    • 22.5.2. Insights from Secondary Research
    • 22.5.3. Insights from In-house Repository

23. GENOME EDITING TECHNOLOGIES MARKET: LEADING INDUSTRY PLAYERS

  • 23.1. Chapter Overview
  • 23.2. Leading Industry Players

24. CONCLUSION

25. EXECUTIVE INSIGHTS

26. APPENDIX 1: TABULATED DATA

27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS